SF3B1+ MDS-RS: IPSS-M-Guided 1L Luspatercept

Jamie L. Koprivnikar, MD, presents a case of a 70-year-old man with SF3B1+ MDS with ring sideroblasts and discusses the approach to initial therapy in patients with lower-risk MDS who may have moderate-to-severe anemia.

A hematologist-oncologist provides expert perspectives on the development and implementation of the IPSS-M as a clinical-molecular prognostic model in lower-risk MDS.

Focusing on molecular prognostic models in LR-MDS, Jamie Koprivnikar, MD, shares insights gleaned from the COMMANDS trial on how mutational burden impacts response.

Jamie Koprivnikar, MD, discusses how findings from the COMMANDS trial can be used to inform treatment decisions for patients based on serum EPO levels and the presence or absence of ring sideroblasts.

Highlighting recent data from a post hoc analysis from the COMMANDS trial, a hematologist-oncologist offers insights on important factors to consider when assessing quality of life in patients with MDS.

Jamie Koprivnikar, MD, discusses factors that signal a need to transition a patient with lower-risk MDS from an ESA to another therapy.

An expert on the treatment of patients with myelodysplastic syndromes provides clinical insights on dosing practices and considerations for luspatercept.

Jamie Koprivnikar, MD, provides key takeaways for optimizing anemia management in patients with lower-risk MDS, highlighting unmet needs in treating anemia and improving patient outcomes.